Sygnature Chemical Services becomes Sygnature Discovery
21 September 2011 | By Sygnature Discovery Limited
Sygnature Chemical Services, has become Sygnature Discovery to better reflect its Integrated Drug Discovery Service-Offering...
List view / Grid view
News
Viramune® (nevirapine) prolonged-release once-daily formulation receives approval in the EU
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
Sanofi Pasteur acquires exclusive, worldwide license for acne vaccine and treatment
21 September 2011 | By Sanofi Pasteur
The pre-clinical vaccine was developed by researchers at the University of California...
Lilly steps up efforts to improve diversity in clinical trials
20 September 2011 | By Eli Lilly and Company
Observational study leads to systemic approach to improve minority enrollment...
Bristol-Myers Squibb and Ono enter into strategic agreement
20 September 2011 | By Bristol-Myers Squibb
Strategic agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)...
Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers
19 September 2011 | By Roche
Data show greater understanding of disease pathways and personalising treatments...
Merck’s ISENTRESS® (raltegravir) in combination therapy demonstrated efficacy and tolerability in an observational trial
19 September 2011 | By
Results from the REALMRK clinical study...
Tecan’s Cavro® Omni Robot opens up new applications for modern circular dichroism
15 September 2011 | By kdm communications limited
Cavro® Omni Robot incorporated into Applied Photophysics’ new protein discovery solution...
GSK and McLaren Group announce innovative strategic partnership
15 September 2011 | By GSK
GlaxoSmithKline announced that it has formed a long term strategic partnership with McLaren Group...
Pfizer extends subsequent offering period of tender offer to acquire Icagen, Inc.
13 September 2011 | By Pfizer
Eclipse, extended the expiration date of the subsequent offering period of its tender offer...
Novartis increases growth potential through integration of Alcon
13 September 2011 | By Novartis
Alcon to accelerate growth through Novartis strength in market access, reimbursement, and research capability...
GSK commits $1 million in cervical cancer vaccine
13 September 2011 | By GSK
A new cooperative effort aimed at reducing deaths from women's cancers...
People with type 2 diabetes experience greater improvements in glycaemic control when using Victoza®
13 September 2011 | By Novo Nordisk
Patient satisfaction when switching from sitagliptin to Victoza®...
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
12 September 2011 | By GSK
The first patient has commenced dosing in a Phase III global registration study...
Analyses find type 2 diabetes patients treated with BYDUREON™ experienced reduction in cardiovascular risk factors
12 September 2011 | By Eli Lilly and Company
Results presented at EASD 2011...
